U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Primary Peritoneal Endometrioid Adenocarcinoma

MedGen UID:
1791628
•Concept ID:
C5555187
•
Neoplastic Process

Definition

Primary peritoneal endometrioid adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Primary Peritoneal Endometrioid Adenocarcinoma

Recent clinical studies

Etiology

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR
J Clin Oncol 2003 Jan 15;21(2):283-90. doi: 10.1200/JCO.2003.10.104. PMID: 12525520

Therapy

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D
J Clin Oncol 2023 Oct 20;41(30):4779-4789. Epub 2023 Jun 26 doi: 10.1200/JCO.22.02624. PMID: 37364223Free PMC Article
Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC
Gynecol Oncol 2006 Jul;102(1):5-7. Epub 2006 May 12 doi: 10.1016/j.ygyno.2006.03.048. PMID: 16697451
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR
J Clin Oncol 2003 Jan 15;21(2):283-90. doi: 10.1200/JCO.2003.10.104. PMID: 12525520

Prognosis

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC
Gynecol Oncol 2006 Jul;102(1):5-7. Epub 2006 May 12 doi: 10.1016/j.ygyno.2006.03.048. PMID: 16697451

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...